8-K
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 4, 2004

RESPIRONICS, INC.


(Exact name of Registrant as specified in its charter)
         
Delaware   000-16723   25-1304989
         
(State or Other Jurisdiction of
Incorporation)
  (Commission File
Number)
  (I.R.S. Employer
Identification Number)
         
1010 Murry Ridge Lane
Murrysville, Pennsylvania
      15668-8525
         
(Address of Principal
Executive Offices)
      (Zip Code)

724-387-5200


(Registrant’s telephone number, including area code)

 


TABLE OF CONTENTS

Item 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
SIGNATURES
INDEX TO EXHIBITS


Table of Contents

Item 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

     On March 4, 2004, Respironics, Inc. issued a press release announcing that it has acquired 100 percent of the outstanding capital stock of Western Biomedical Technologies (WBT), an Ireland-based company, which owns 100 percent of the outstanding capital stock of Caradyne Limited (Caradyne), also an Ireland-based company. In that press release, Respironics, Inc. also reported that it will not be changing its financial outlook or guidance for fiscal year 2004. A copy of the press release is attached hereto as Exhibit 99.

Exhibits

     
99
  Press release, dated March 4, 2004, issued by Respironics, Inc.

2


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  RESPIRONICS, INC.
 
       
  By:   /s/ Daniel J. Bevevino
       
      Daniel J. Bevevino
      Vice President, and Chief Financial and
      Principal Accounting Officer

Dated: March 4, 2004

3


Table of Contents

INDEX TO EXHIBITS

     
Exhibit No.   Description

 
 
   
99
  Press release, dated March 4, 2004, issued by Respironics, Inc.

4